Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance (TradingView) - Sep 1, 2026 - "Incyte will enable state Medicaid access to Jakafi and Jakafi XR at prices aligned with a defined group of advanced, industrialized nations. Under the agreement, Incyte expects not to be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models.
Company does not expect the agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook."
Reimbursement • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera
|